Purpose/Objective(s): To investigate the relationship between tumor mutation burden (TMB) and driver mutations and their role as predictive biomarkers to guide targeted therapy in pediatric brain tumors. Higher TMB has been found to relate to lower incidence of driver mutations, but this relationship has not been studied in pediatric brain tumors. Materials/Methods: To characterize the association between TMB and known driver mutations, comprehensive genomic profiling (CGP) was performed on 723 pediatric (≤21 years) brain tumor samples using DNA extracted from 40 microns of formalin-fixed paraffin-embedded tissue. CGP utilized hybridization-captured, adaptor ligation-based libraries sequenced to a mean coverage depth of >500X for up to 315 cancer-related genes. TMB was calculated as mutations per megabase and categorized as low (0-6), intermediate (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), or high (20+). Analysis included 80 clinically relevant driver mutations; genomic alterations known to confer a selective growth advantage.
integration of genomic biomarkers into brain tumor classification has advanced the development of molecularly stratified clinical trials and the need to characterize tumors by genomic signature. Methods: Comprehensive genomic profiling (CGP) was performed on FFPE material from 6304 consecutive cases of pediatric and adult brain tumors initially diagnosed by submitting institutions based on histology. We analyzed tumors via CGP in 395 cancer-associated genes (including IDH1/2) and for 1p/19q codeletion using a validated algorithm. Results: Of 6304 brain tumor samples, known IDH point mutations included 1182 IDH1 R132, 50 IDH2 R172, and 1 IDH2 R140 variants. In the IDH-mutant cohort, 1p/19q codeletion was detected in 72% (260/363) of histologically defined oligodendrogliomas (ODGs), 21% (17/82) of oligoastrocytomas (OAs), 6% (22/360) of glioma (NOS, not otherwise specified), 4% (2/50) of gliosarcomas, 3% (26/859) of astrocytomas (NOS), and 1% (32/3200) of glioblastomas. ODG with 1p/19q loss were enriched for TERT, CIC, and FUBP1 alterations, whereas 1p/19q intact tumors were enriched for TP53 and ATRX alterations. Actionable alterations in ODG included 8% (29/363) with high tumor mutational burden (potential immunotherapy responsiveness) and 15% (56/363) with PIK3CA mutation. Analysis of OA (mixed glioma) revealed genomic subtypes similar to well-defined gliomas including ODGs 1p/19q loss, TERT, CIC, FUBP1), diffuse astrocytomas (IDH-mutant, TP53, ATRX), and high-grade gliomas (IDH-wild-type, EGFR, NF1). Conclusions: Using cooccurring IDH mutation and 1p/19q codeletion as the diagnostic signature of ODG, we show that as many as 25% may be misclassified on morphologic criteria alone. OAs exhibit genomic features of defined glioma subtypes, suggesting CGP may provide diagnostic clarity in this setting. This study highlights how CGP can improve diagnostic accuracy and provide additional treatment options for patients.
(119/125) of tumors. BRAF was most frequently altered (48%; 60/125), and FGFR1 missense (17.6%; 22/125), NF1 loss of function (8.8%; 11/125), and TP53 (5.6%; 7/125) mutations were also detected. Rearrangements were identified in 35% of pLGGs, including KIAA1549-BRAF, QKI-RAF1, FGFR3-TACC3, CEP85L-ROS1, and GOPC-ROS1 fusions. Among pHGGs, GA were identified in 96. 8% (152/157 Comprehensive genomic profiling of pediatric gliomas provides objective data that promote diagnostic accuracy and enhance clinical decision-making. Additionally, TMB could be a biomarker to identify pediatric glioblastoma (GBM) patients who may benefit from immunotherapy.
Similar articles

View similar articles on Embase.com
Copyright
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Records
Comprehensive genomic profiling identifies genomic alterations that define philadelphia-like b-acute lymphoblastic leukemia
Severson E.A., Gay L.M., Daniel S., Elvin J.A., Suh J., Nahas M., Miller V.A., Stephens P.J., Ross J.S., Ramkissoon S., Vergilio J.-A.
Blood 2017 130 Supplement 1
Embase
Open URL: full text Abstract BACKGROUND: Philadelphia-like B-Acute Lymphoblastic Leukemia (Ph-like B-ALL) shares a similar gene expression profile with BCR-ABL positive B-ALL, but lacks the BCR-ABL fusion. Of all B-ALLs, ∼10% of pediatric (<=18), ∼30% of young adult (19-39), and ∼20% of adult (>=40) B-ALLs are Phlike. Although Ph-like B-ALL has a poor prognosis with standard of care treatment, case studies have demonstrated responses to targeted therapies, such as inhibitors of JAK or other tyrosine kinases. Gene expression profiling to identify Ph-like B-ALL is not yet widely available in routine clinical practice and identifying these cases is challenging. However, it has been previously reported that ∼80% of Ph-like cases have genomic alterations that activate the JAK-STAT pathway or other kinases, and case studies show that targeting these alterations is a promising strategy for treating these poor risk patients. DESIGN: 313 cases of B-ALL were evaluated by comprehensive genomic profiling (CGP) for 406 genes via DNAseq for all classes of genomic alterations (GA) and 265 genes via RNAseq for rearrangements, using a CAP-accredited, CLIA-certified, NYS-approved hybrid-capture nextgeneration sequencing assay (FoundationOne Heme ). RESULTS: A total of 45/313 samples (14%) had BCR-ABL fusions, with a decreased prevalence likely due to samples having been pre-screened for BCR-ABL by other assays, leaving 268 BCRABL-negative B-ALLs.
The BCR-ABL positive samples are excluded from the remaining analyses. The BCR-ABL negative cohort (n=268) was 46% female and 54% male (median age 23 y, range 1-89 y). At least one rearrangement was detected in 163 cases (61%), and the overall mean was 4.1 GA per case. Kinase fusions were detected in 61 cases (22.4%), 56 (20.8%) cases had JAK-STAT pathway activating mutations, and 9 (3.3%) cases had activating mutations in other kinases (Table 1 ). In total, 98/268 (36.5%) BCR-ABL negative B-ALL cases sequenced had at least one GA consistent with Ph-like B-ALL.
Consistent with the known higher rate of Ph-like B-ALL in young adults, 35.1% of pediatric, 45.3% of young adult, and 30% of adult BCR-ABL negative B-ALL cases had Ph-like alterations. The Ph-like B-ALL cohort (n=98), as defined by GA, was 43% female and 57% male, consistent with prior reports that Ph-like B-ALL is more common in men.
The types of alterations present varied by age group. Pediatric and young adult cases more likely harbored kinase fusions (70% and 73.5%), compared to adult cases (50%).
Conversely, pediatric cases were least likely to have Ph-like point mutations or indels (50%), compared to young adult and adult cases (65% and 67%). Specifically, adults were more likely to have FLT3 and CRLF2 point mutations/indels, whereas young adults were more likely to have CRLF2 fusions and JAK2 point mutations (Table 1) . Of the 98 Ph-like B-ALL cases, 29 (29.6%) also had RAS pathway alterations (KRAS, NRAS, PTPN11, or NF1). The remaining samples (n=170) -representing BCR-ABL negative, Ph-like alteration negative cases -was 49% female and 51% male (median age 24, range 1-89). GA were most often detected in CDKN2A and/or CDKN2B (33%), TP53 (25%), KRAS (15%), NRAS (14%), or RB1 (11%); ETV6-RUNX1 fusions were identified in 15% of samples. CONCLUSIONS: Approximately 80% of Ph-like B-ALL cases can be identified by the detection of GA affecting the JAK-STAT pathway or other kinases. Thus, a significant subset of Ph-like B-ALL cases can be identified through CGP that includes extensive fusion detection. In our cohort, 36.4% of BCR-ABL negative patients had alterations consistent with Ph-like B-ALL, with the highest rate of GA detection in young adults. Improved therapy is critical in this population of patients, who typically fail induction or relapse early with current standard of care therapies. Case studies have reported success in treating patients with Ph-like B-ALL by targeting the driver alteration with inhibitors of JAK or other tyrosine kinases. CGP is currently clinically available as CLIA-certified assays and can be utilized to identify patients with Ph-like B-ALL containing targetable alterations to determine prognosis and identify treatment options.
( Table Presented) .
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View similar articles on Embase.com of known recurrent mutations (ex: FLT3, JAK2, TET2), but its overall prevalence and involvement in AML pathogenesis has yet to be determined. Initial studies regarding the significance of CNVs suggest possible prognostic impact. We aimed to explore the prevalence of segmental CNVs and CN-LOH in a cohort of pediatric and adult AML specimens that underwent clinical comprehensive genomic profiling (CGP) (FoundationOne Heme Sequencing). Methods: CGP for targeted DNA and RNA sequencing was performed on 932 patients with AML (n=179 pediatric age ≤ 18 years, n=753 adult age ≥ 19 years). Specimen sites included bone marrow, peripheral blood, and biopsy of extramedullary disease. Following strict quality control (QC) measures to exclude any samples with transplant history, contamination, low purity, and lack of aneuploidy, all level CNV and LOH events were reported using a proprietary algorithm. A total of 323 samples met QC standards for LOH events, with all level copy number analyses available for 236 (73%) patients. We analyzed the loci of 91 genes to determine the type and prevalence of CNV events for amplifications (CNA; CN>2), deletions (CND; CN<2), CN-LOH, copy-loss LOH (CL-LOH) events at the genomic or chromosome level excluding sex chromosomes. Results: Among the 323 samples (n=59 pediatric, n=264 adult), the prevalence of LOH events was 91% (294). Identified LOH events included single gene LOH or chromosomal LOH, including arm or whole chromosome. Chromosomal events occurred in 172 (53%) of patients, and most frequently involved the following arms: 7q (n=59), 7p (n=57), 13q (n=25), 18q (n=23), 18p (n=22), 5q (n=19), and 17p (n=19). Among patients with chromosomal LOH events, 131 (76%) had events in the 7 chromosomal arms with the highest frequency ( Fig 1A) .
Genomic LOH events were detected in 287 (89%) patients, and were detected in all 91 of the genes analyzed, with a frequency of 1-58. Further, CN-LOH events were detected in 162 (50%) patients occurring in 89 (98%) of genes analyzed (Fig 1B) , with a frequency of 1-17. Among the 20 genes with highest frequency of LOH, 11 of them occurred at the 7q and 13q regions, which is consistent with previous findings that these are areas of frequent genomic losses. LOH, including CN-LOH, events overall commonly occurred in genes located in the 5q, 7p, 13q, 16q, and 17p regions. Recurrent LOH events in 3 of the most commonly affect genes occurred in approximately 31% of patients (EZH2, n=103, BRAF, n=102, and KMT2C, n=99), all located on 7q. CN-LOH events were detected in oncogenes such as CDK6, MET, FLT3, JAK2, ABL1. Among the 236 samples evaluable for CNA assessment, 217 (92%) had at least one CNA or CND detected. CNAs were detected in 163 patients (69%) and occurred in all 91 of the genes analyzed ( Fig 1C) .
Among samples with CNAs detected, the median number of somatically acquired CNAs was 5 (range 1-91). Recurring CNAs were detected across all chromosomes, but were most common in genes located on chromosome 1q, 8, 11q, 13q, 17q, 19, and 21q. CNDs were detected in 165 patients (70%) and occurred in 83 of genes (91%) analyzed. tyrosine kinase inhibitor (TKI) for patient benefit. We undertook a large-scale genomic analysis to describe the frequency of 4q12 across solid tumors. Methods: We prospectively analyzed 114,200 primarily advanced stage solid tumors in the course of clinical care using hybrid-capture based comprehensive genomic profiling (CGP) of 186 to 315 genes plus introns from 14 to 28 genes commonly rearranged in cancer. Results:
4q12amp was present in 0.65% of all cases (740/114,200) , with a median copy number of 10, and was most abundant in the following cancers: 4.8% of GBM (155/ 3,222), 0.83% of lung cancers (191/22,857, 2/3 approximately being LA), 1.9% of sarcomas (106/5,391), and 0.77% of breast cancers (92/11,980) . Of sarcomas, 7.1% of osteosarcomas (26/367) and 2.82% of soft tissue sarcomas NOS (22/780) harbored 4q12amp. Of 4q12amp lung cancer cases, the supramajority (86%) did not harbor known oncogenic drivers of NSCLC (alterations of EGFR/HER2/MET, ALK/ROS/RET fusions, or BRAF V600E). Index cases of durable responses to pazopanib and imatinib will be described in undifferentiated sarcoma, synovial sarcoma, and head and neck/ salivary cancers. Conclusions: 4q12amp is significantly less frequent in GBM and lung cancer than previously reported by non-sequencing techniques, but is enriched in osteosarcoma and undifferentiated sarcomas. The driver status of 4q12amp is supported both by the predominant mutual exclusivity with other known drivers in lung cancer, and responses to various multi-TKIs. The specificities of the latter may help shed insight into whether singly or multiply targeting KIT/KDR/PDGFRA is a preferred approach for patient benefit.
Background: The frequency of genomic alterations in cancer is known to differ based on a patient's age. Many studies have characterized the genomic characteristics of pediatric cancers; however, less is known about how the genomic landscape of mutations changes with age in adult patients. Accurately characterizing these differences will help guide personalized treatment strategies and illuminate differences in the genetic etiology of cancer at different ages of onset. Methods: Comprehensive genomic profiling was performed on > 100,000 patients in the course of routine care for patients with predominantly relapsed, refractory or metastatic cancer. For 117 types of cancer with ≥ 100 cases, logistic regression was used to identify genomic features with statistically significant dependence on patient age. Results: Many known associations with age were identified, including increased prevalence of BRCA1/2 mutations in younger breast and ovarian cancer patients and increased prevalence of mismatch repair mutations in younger colorectal and endometrial adenocarcinoma patients. In lung adenocarcinoma, we identified 19 genes for which alteration prevalence was significantly associated with patient age. The genes ALK, ROS1, and RET were more commonly altered in younger patients, KRAS and MET were altered more frequently in older patients, and TP53 was most frequently altered at intermediate ages . Interestingly, a set of genes that have previously been associated with clonal hematopoiesis (CH) were found to be more frequently detected in older patients across a wide variety of cancer types. Based on the statistical power provided by this large cohort, several novel age based differences in gene alteration rates across multiple tumor types were detected and will be presented.
Conclusions: Clear differences in genomics based on patient age were observed. This methodology can be used to identify novel associations between germline alterations and cancer types and somatic alterations that occur predominantly in young or elderly patients. These results also highlight the importance of accurately identifying and properly reporting somatic CH mutations during tumor genomic profiling.
with the potential to mitigate effects. However, the majority of targeted therapy options are currently not available for childhood cancer. Our cohort showed high incidence for the identification of genomic alterations in children with solid tumors. However targeted therapy options for our patients were limited at present time. It is promising that an increased number of pediatric patients tolerate targeted therapy, and that an improvement in outcomes have been reported in the literature. Promising data in adult counterparts indicates that research should continue into identifying potential targets for therapy, as well as developing future therapies.
analyzed the results of samples from 71 patients sequenced on the FoundationOne® Heme assay from children and young adults with acute lymphoblastic leukemia (ALL) (n= 34); early T cell precursor ALL (ETP) (n=3); acute myelogenous leukemia (AML) (n= 19); ambiguous lineage leukemia (n=3); and myelodysplastic syndrome (MDS) (n=12) who were treated at Memorial Sloan Kettering Cancer Center in the Department of Pediatrics over a 26 month period (January 2014-March2016). Age of patients ranged from 1-24 years of age (median =10 years). 42 samples were from patients who had yet to receive cytotoxic therapy (newly diagnosed) and 29 samples were from patients who had relapsed (n=24) or had refractory disease (n=5). The current average turnaround time for FoundationOne® Heme is 12-14 days. Overall 99% (70/71) of specimens were successfully profiled. We identified 230 genomic alterations, including 59.1% (136/230) missense or nonsense mutations of genes, 15.6% (36/230) copy number alterations, and 25.6% (59/230) gene fusions or rearrangements. Molecular aberrations were detected in 81% (9/11) of patients with normal karyotypes; 55% (5/9) of these were cytogenetically cryptic genomic rearrangements including NUP98-NSD1 (n=2) and 1 MLL-PTD (n=1).
We identified one novel translocation involving SATB1-PDGFRB in a sample from a patient with pre B ALL. Another patient with pre B ALL was found to have a unique combination of genomic alterations including an MLL-PTD and SSBP2-JAK2. Two patients with MDS were identified as harboring germline GATA2 mutations, indicating the likely benefit of an allogeneic hematopoietic stem cell transplantation. Three patients had therapy modifications based on findings with the addition of dasatinib (ZMIZ1-ABL1), ruxolitinib (PCM1-JAK2) and trametinib (PTPN11mutation), and two patients had risk stratification altered based on MLL rearrangements which were not identifiable by conventional cytogenetics. Overall, the use of comprehensive genomic profiling led to improved accuracy of diagnosis or alteration of therapy in 10% (7/71) cases, including molecular based therapy selection (n=3), escalation of conventional chemotherapy due to high-risk features (n=2), and inclusion of stem cell transplantation (n=2). Thus, clinical genomic profiling of pediatric acute leukemia led to discovery of new pathobiology, improved accuracy of clinical diagnosis, and inclusion of targeted molecular therapies.
( Figure presented) .
Background: The NTRK, neurotrophic tyrosine kinase receptor, genes encode proteins essential for normal neuronal growth and development. Fusions of NTRK family members have recently been linked to oncogenesis as well as identified as potential targets of therapy. In this study, a hybrid capture based comprehensive genomic profiling (CGP) assay was used to study a large series of pediatric solid tumors to search for NTRK gene fusions. Methods: CGP using hybridization capture of at least 3, 320 exons from 182 cancer-related genes and 37 introns of 14 genes commonly rearranged in cancer (previous version of the test) was applied to ≥ 50ng of DNA extracted from 1351 pediatric/adolescent/young adult tumors (<22). Results:, From 1351 pediatric/adolescent young adult advanced cancer patients, 7 (0.52%) harbored NTRK family member fusions. Of these, 5 were pediatric (<18 years) (0.51% from 986 total cases). Ages of the patients ranged from <1 to 22 years, with 4 cases being <5 years and included 5 males and 2 females. Histologic diagnoses of these neoplasms were 2 soft tissue fibrosarcomas, soft tissue sarcoma NOS, soft tissue solitary fibrous tumor, soft tissue hemangioma, soft tissue schwanoma and a soft tissue dendritic cell neoplasm. The fusions identified were LMNA-NTRK1 (twice) and SQSTM1-NTRK1, TPM3-NTRK1, TPR-NTRK1, TFG-NTRK3, and ETV6-NTRK3. Four (57%) of 7 of these patients also harbored a CDKN2A/B homozygous deletion. Other genomic alterations in these cases included in one case each: PTRPO R231H, EP300 E628fs * 7, MAP3K14 R218fs * 731 and KDM4C amplification. One case was that of a 1.5 year old boy initially diagnosed with infantile fibrosarcoma (IFS) on a morphologic basis. CGP demonstrated his tumor harbored LMNA-NTRK1 and CDNK2A/B loss, and the patient then received crizotinib for pulmonary and skeletal metastases. He achieved an ongoing complete response exceeding 8 months. Conclusions: 0.5% pediatric/adolescent/young advanced cancers harbor NTRK1 and NTRK3 fusions, and all such tumors are mesenchymal in origin. Of these, an index case benefitted from crizotinib treatment, suggesting pathways to clinical benefit for such cases.
INTRODUCTION Tumor mutation load is a biomarker of emerging significance in cancer immunotherapy. Both mutation load and neoantigen load, as measured by whole exome sequencing, have been shown, in several tumor types, to correlate with patient response to both CTLA4 and PD1 inhibition. Consequently, understanding the factors associated with increased tumor mutational burden is critically important to cancer patient treatment decisions. We sought to better understand the landscape of tumor mutation load and potential response to immunotherapy based on data from comprehensive genomic profiling (CGP) of ∼60,000 tumors from patients across ∼400 cancer types. METHODS CGP profiling by hybridization capture of exonic regions from 236 or 315 cancer-related genes and select introns from 19 genes commonly rearranged in cancer was applied to ≥ 50ng of DNA extracted from >60,000 clinical FFPE cancer specimens. These libraries were sequenced to high, uniform median coverage (>500x) and assessed for base substitutions, short insertions and deletions, copy number alterations and gene fusions/re-arrangements. Mutation load was accessed as the number of somatic, coding, base substitution and indel mutations, per megabase of genome examined. RESULTS
We first validate that mutation load calculated based on CGP of the entire coding region of 315 genes (∼1.3 MB) provides a representative measurement of genome-wide mutational load. We quantify and provide detailed data describing mutation load across common tumor types and identify recurrent somatic mutations that are associated with significant increase in tumor mutation load. Our analysis expands significantly upon existing data that quantifies mutation load in hundreds of additional cancer types. Lower grade and pediatric malignancies were observed to have the lowest somatic mutation load, while diseases with significant known mutatgenic exposure such as lung and skin cancers were most highly mutated. Finally, the genomic alterations most associated with increased mutation load were loss of function mutations in mismatch-repair genes (MSH2, MSH6, MLH1 and PMS2), DNA replication genes (POLD1, POLE) and in TP53.
CONCLUSION These data demonstrate that tumor mutational load can be accurately quantified using targeted CGP with a CLIA-certified assay that is already integrated into routine patient care. As the role of mutation burden as a biomarker for patient response to immune therapy becomes established, this approach can be used to identify both targeted and immune therapeutic options that are either approved or in clinical trial.
Additionally, by characterizing the landscape of mutation load across the full spectrum of human cancer, we provide new data for the rational expansion of the patient population that can potentially benefit from immunotherapy.
